Review Article

Oxidative Stress Links Aging-Associated Cardiovascular Diseases and Prostatic Diseases

Ming-Juan Zhao,¹ Shuai Yuan,¹ Hao Zi,¹,² Jia-Min Gu,¹,² Cheng Fang,¹ and Xian-Tao Zeng¹,²

¹Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Hubei, Wuhan 430071, China
²Department of Urology, Zhongnan Hospital of Wuhan University, Hubei, Wuhan 430071, China

Correspondence should be addressed to Cheng Fang; vitsippa@whu.edu.cn and Xian-Tao Zeng; zengxiantao1128@whu.edu.cn

Received 12 May 2021; Revised 17 June 2021; Accepted 3 July 2021; Published 19 July 2021

Academic Editor: Yue Liu

Copyright © 2021 Ming-Juan Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The incidence of chronic aging-associated diseases, especially cardiovascular and prostatic diseases, is increasing with the aging of society. Evidence indicates that cardiovascular diseases usually coexist with prostatic diseases or increase its risk, while the pathological mechanisms of these diseases are unknown. Oxidative stress plays an important role in the development of both cardiovascular and prostatic diseases. The levels of oxidative stress biomarkers are higher in patients with cardiovascular diseases, and these also contribute to the development of prostatic diseases, suggesting cardiovascular diseases may increase the risk of prostatic diseases via oxidative stress. This review summarizes the role of oxidative stress in cardiovascular and prostatic diseases and also focuses on the main shared pathways underlying these diseases, in order to provide potential prevention and treatment targets.

1. Introduction

Cardiovascular diseases (CVDs), including hypertension, coronary heart disease (CHD), cerebrovascular disease, and heart failure, are the major cause of death globally. In the period from 1990 to 2019, the prevalence of total CVD nearly doubled from 271 million to 523 million cases, and the number of CVD deaths steadily increased from 12.1 million to 18.6 million [1]. In 2019, ischaemic heart disease was one of the top-ranked causes of disability adjusted life years (DALYs) in both the 50-74-year and 75-years-and-older age groups [2]. According to World Health Organization (WHO) statistics, almost 23.6 million people will die from CVDs by 2030. Benign prostatic hyperplasia (BPH) and prostate cancer are also aging-associated diseases. The incidence rate of BPH increases with age affecting about 50% of men over 50 years, increasing to 80% when they reach 80 or above [3, 4]. There is also an increased incidence in prostate cancer cases from 940,000 in 2007 to 1.3 million in 2017 [5], and the age-standardized incidence of prostate cancer in China also rose by 2.75% from 1990 to 2017 [6]. Aging clearly plays an important role in CVDs (such as hypertension and CHD) and prostatic diseases (prostate cancer and BPH).

The current evidence suggests that CVDs usually coexist with prostatic diseases or increase its risk, and there are 13 related clinical studies showing CVD as a risk factor for prostatic diseases (see Table 1); however, whether there is a causal relationship between them is still controversial. Numerous studies have reported that oxidative stress can promote the occurrence and development of both prostatic diseases and CVDs [7–10]; hence, to summarize its role in these two diseases can provide information for seeking prevention and potential therapeutic targets.

2. Oxidative Stress

The concept of oxidative stress originated from human understanding of aging. In 1956, Professor Harman first proposed the theory of free radical aging. In 1990, Professor Sohal pointed out the flaws of this theory and put forward the concept of oxidative stress for the first time [24, 25].
table 1: Epidemiological studies about the associations of CVD and prostatic diseases.

| Author (year) | Country | Study design | Disease diagnosis | Prostatic diseases | Sample size | Age (year) | Main outcomes | Reference |
|---------------|---------|--------------|-------------------|--------------------|-------------|------------|--------------|----------|
| Bourke J B, et al. 1966 | UK | Case control | HP (SBP > 200 mmHg and DBP > 110 mmHg) | BPH (diagnosed histologically) | 432 | 65-69 | The incidence of HP in patients who were operated upon for BPH was significantly greater than control series. | [11] |
| Sugaya K, et al. 2003 | Japan | Cohort study | HP (SBP ≥140 mmHg or DBP>90 mmHg) | BPH (digital rectal examination and ultrasonography) | 42 | NT group: 69 ± 8 HT group: 71 ± 11 | HP may worsen LUTS. | [12] |
| Michel M C, et al. 2004 | Germany | Case control | HP (DBP > 90 mmHg or with history of hypertension or receiving antihypertension medication) | BPH (diagnosed by urologist) | 9857 | Mean: 65.1 | Patients with HP had more severe BPH symptoms and that more severe BPH symptoms are associated with a high HP. | [13] |
| Chen I H, et al. 2012 | China | Case series | HP (the history of hypertension) | BPH (IPSS > 8 and PV > 18 cm³) | 130 | 60.9 ± 10.8 | The more cardiovascular risk factors in patients with BPH, the greater was the prostate vascular resistance. | [14] |
| Hwang E C, et al. 2015 | South Korea | Case control | HP (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or with a previous diagnosis of hypertension and receiving medical treatment) | BPH (transurethral resection of the prostate) | 295 | 69.5 ± 7.0 | Men with HP were more likely to have greater LUTS and larger prostate volume. | [15] |
| Zeng XT, et al. 2018 | China | Cross-sectional study | HP (NR) | BPH (NR) | 350 | NT group: 71.5 ± 7.4 HT group: 70.7 ± 7.3 | HP had no significant association with prostate volume. | [16] |
| Navin S, et al. 2017 | US | Cross-sectional study | HP (NR) | PCa (NR) | 3200 | 51-76 | Patients with PCa had a significantly higher prevalence of HP than the general population. | [17] |
| Dickerman B A, et al. 2018 | Iceland | Cohort study | HP (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or taking anti-hypertensives) | PCa (morphologically verified) | 9097 | 52.1 ± 8.4 | This was a positive association between midlife hypertension and aggressive PCa. | [18] |
| Weisman KM, et al. 2000 | US | Case control | CHD (included the history of coronary artery bypass graft, coronary angioplasty, and myocardial infarction) | BPH (prostate biopsy and transurethral resection of the prostate) | 140 | 65-80 | Patients without BPH had a lower frequency of CHD than those with BPH. | [19] |
| Neugut AI, et al. 1998 | US | Case control | CHD (the history of myocardial infarction, coronary artery bypass graft, positive coronary angiogram, or positive exercise stress test) | PCa (diagnosed pathologically) | 508 | Case group: 69.6 ± 9.1 Control group: 68.1 ± 9.0 | The individuals with CHD are at elevated risk for PCa. | [20] |
| Stamatiou KN, et al. 2007 | Greece | Case serials | CHD (pathologic examination) | PCa (histological features) | 116 | 55-98 | There could be an association between CHD and PCa. | [21] |
**Table 1: Continued.**

| Author (year)         | Country | Study design | Disease diagnosis | Prostatic diseases | Sample size | Age (year) | Main outcomes                                                                                     | Reference |
|-----------------------|---------|--------------|-------------------|--------------------|-------------|------------|--------------------------------------------------------------------------------------------------|-----------|
| Thomas JA 2nd, et al. 2012 | US      | Clinical study | CHD (post history) | PCa (biopsy and PSA) | 6729        | 50-75      | CHD was significantly associated with PCa diagnosis.                                              | [22]      |
| Omalu BI, et al. 2013 | US      | Case serials | CHD (two forensic pathologists and a senior pathology resident) | PCa (two genitourinary pathologists for histologic) | 37          | 65.8 (50-86) | There was no association between degree of CHD and PCa.                                          | [23]      |

*HP: hypertension; BPH: benign prostatic hyperplasia; SBP: systolic blood pressure; DBP: diastolic blood pressure; NT: normotensive; HT: hypertensive; PCa: prostate cancer; IPSS: international prostate symptom score; LUTS: lower urinary tract symptoms; NR: not reported; PV: prostate volume; CHD: coronary heart disease.*
Oxidative stress is a situation where the balance of oxidative systems and antioxidative systems in vivo is changed in favor of the former [26, 27]. Oxidants are regulators of normal cellular function, but when the production of reactive oxygen species (ROS) exceeds the scavenging capacity, the oxidation and antioxidant systems will be unbalanced, causing damage to the tissues and cells; this phenomenon is called oxidative damage [28–30]. ROS includes superoxide anion (O₂⁻), hydroxyl radical (OH), and hydrogen peroxide (H₂O₂). To maintain the balance, there are two antioxidative systems in vivo: one is the enzyme antioxidant system, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-PX), and the other is the non-enzyme antioxidant system which includes vitamin C, vitamin E, glutathione, melatonin, α-lipoic acid, carotenoids, and trace elements such as copper, zinc, and selenium.

2.1. Characteristics of ROS. ROS are generated by a variety of extracellular and intracellular actions (Figure 1). The main intracellular source of ROS is the mitochondrial respiratory chain. The O₂⁻ is the principal ROS formation which is produced by the enzymatic reaction and a nonenzymatic electron transfer reaction in cell. The enzymes that generate the superoxide include NADPH oxidase (NOX), xanthine oxidase (XO), lipoxygenase (LOX), and cyclooxygenase (COX) [31]. H₂O₂ is produced from O₂⁻ by enzymatic dismutation by the three isoforms of Cu/Zn/Mn SOD in intracellular. Most of the H₂O₂ is converted to H₂O by the catalase (CAT), glutathione peroxidase (GPX), and peroxidases (PRX). H₂O₂ can damage DNA when it is converted to OH through Fenton and Haber-Weiss reactions in the transition metal ions, especially iron ions (Fe⁺²). The OH is the most toxic form of ROS which causes various types of DNA damage, lipid peroxidation, and protein modification [32]. The extracellular sources of ROS commonly included pollution, inflammation, cigarette smoke, radiation, and medication [33].

At present, accurately measuring ROS in disease is still a problem. ROS are unstable, and their half-lives are relatively short. For example, the half-life of O₂⁻ is 10⁻⁶ to 10⁻⁹ seconds, and the OH is 10⁻⁹ seconds [34, 35]. Therefore, ROS are routinely measured by biomarkers of oxidative damage, which included markers of protein damage (protein carbonyl derivatives), lipid peroxidation (malondialdehyde [MDA] and 4-...
Table 2: The summary of oxidative stress in CVD or prostatic diseases.

| Author (year) | Study design | Study population | Age (year) | Markers assessed | Main results | Reference |
|---------------|--------------|------------------|------------|------------------|--------------|-----------|
| Germanò G, et al. 2004 | Cross-sectional study | 40 persons with HP and 40 healthy individuals | 15-80 | (iii) GST and GSH activities measured by spectrophotometry | Patients with hypertension showed an enhanced formation of $O_2^-$ in platelets. | [37] |
| Guxens M, et al. 2009 | Cross-sectional study | 819 CHD patients with HP and 311 CHD patients without HP | 40-80 | (i) Circulating ox-LDL measured by an enzyme-linked immunosorbent | There was a positive relationship between circulating ox-LDL and hypertension. | [38] |
| Pinzón-Díaz CE, et al. 2018 | Clinical trial study | 12 persons with HP and 15 healthy individuals | 25-60 | (i) MDA by a spectrophotometer and GSH concentration used the glutathione assay kit | Compared to healthy patients, the level of lipid peroxidation is higher 2.1 times in hypertensive patients. | [39] |
| Zhao H, et al. 2018 | Clinical trial study | 75 people with HP and 75 healthy people | 40-80 | (i) Melatonin measured by metabolomic | Oxidative stress would cause disturbance in hypertensive patients and affect the metabolic pathway of pathogenesis. | [40] |
| Merendino RA, et al. 2003 | Clinical study | 22 patients with BPH and 22 healthy subjects | 50-80 | (i) MDA measured a commercially kit | The results showed a higher level of MDA in BPH patients. | [44] |
| Camphausen K, et al. 2004 | Cohort study | 38 radiotherapy PCA cases and 15 received placebo | NR | (i) Urinary 8-iso-prostaglandin PGF$_2\alpha$ and 15-keto-dihydro-PGF$_2\alpha$ | The study showed that there was no statistically increase in 8-iso-PGF$_2\alpha$ or 15-keto-dihydro-PGF$_2\alpha$ in patients with PCA compared with normal control group. | [45] |
| Yilmaz MI, et al. 2004 | Case-control study | 50 patients with BPH and 21 patients with PCA and 50 healthy subjects | 50-80 | (i) CuZn-SOD, and GPX measured by a UV–VIS recording spectrophotometer | Compared with BPH and control groups, there is a higher MDA concentration with lower GPX and CuZn-SOD activities in PCA patients. | [46] |
| Srivastava DS, et al. 2005 | Case-control study | 55 patients with BPH and 45 patients with PCA and 25 healthy individuals | 50-80 | (i) GPX measured by kit and (ii) MDA | Compared with control group, there is a higher level of MDA concentration and GST activity and lower levels of GSH concentration and GPX activity in BPH and PCa groups. | [47] |
| Aydin A, et al. 2006 | Clinical study | 36 patients with BPH and 25 patients with PCA and 24 healthy subjects | 50-80 | (i) The level of TBARS, SOD, GPX, CAT, Cu, and Zn | Compared with control group, the lipid peroxidation was increased with decreased SOD activity in BPH and PCa groups. | [48] |
| Surapaneni KM, et al. 2006 | Case-control study | 30 patients with PCA and 30 healthy cases | NR | (i) MDA measured by spectrophotometry and (ii) SOD measured by Misra and Fridovich and (iii) GST and GSH activities measured by spectrophotometry | Compared with control group, there is a higher level of MDA and SOD and lower level of GSH in PCa patients. | [49] |
| Author (year) | Study design | Study population | Age (year) | Markers assessed | Main results | Reference |
|--------------|--------------|------------------|------------|------------------|--------------|-----------|
| Ozmen H, et al. 2006 | Cross-sectional study | 20 patients with PCa 21 healthy cases | PCa group: 72.45 ± 7.78  Control group: 66.33 ± 8.25 | (i) MDA and vitamins measured by HPLC  (ii) SE measured by a fluorimetric method  (iii) Trace elements and Fe measured by atomic absorption spectrophotometry | The study showed that the administration of vitamins A, C, and E and SE and Zn may be beneficial in the prevention and treatment of human prostate cancer. | [50] |
| Lockett KL, et al. 2006 | Case-control study | 158 patients with PCa 128 healthy cases | PCa group: 65 ± 3  Control group: 63.4 ± 8 | (i) DNA damage evaluated by alkaline comet assay | The study suggested that DNA damage may be associated with PCa risk. | [51] |
| Aryal M, et al. 2007 | Case-control study | 48 patients with BPH 46 healthy cases | BPH group: 67 ± 3  PCa group: 67 ± 4  Control group: 65 ± 7 | (i) Lipid peroxide was estimated by spectrophotometry  (ii) Protein carbonyls measured by modified Levine’s | Compared with control group, there is a higher level of lipid peroxides and protein carbonyls in patients with BPH or PCa, and PCa patients are more prone to oxidative damage in compared with BPH patients. | [52] |
| Goswami K, et al. 2007 | Case-control study | 10 patients with BPH 10 patients with PCa 10 control subjects | BPH group: 65 ± 3  PCa group: 67 ± 4  Control group: 65 ± 7 | (i) MDA  (ii) α-Tocopherol and ascorbate | Compared with control group, there is a higher level of plasma MDA and lower plasma alpha-Tocopherol and ascorbate level in patients with BPH. | [53] |
| Arsova-Sarafinovska Z, et al. 2009a | Case-control study | 67 patients with BPH 73 patients with PCa 23 control subjects | BPH group: 64.3 ± 7.9  PCa group: 67.5 ± 8.8  Control group: 65.0 ± 6.0 | (i) MDA  (ii) CuZn-SOD, GPX, and CAT measured by a UV–VIS recording spectrophotometer  (iii) NO2−/NO3− concentration with higher MDA and NO2−/NO3− concentration with lower GPX and CuZn-SOD activities in PCa patients. | Compared with BPH and control groups, there is a higher MDA and NO2−/NO3− concentration with lower GPX and CuZn-SOD activities in PCa patients. | [54] |
| Arsova-Sarafinovska Z, et al. 2009b | Case-control study | 100 patients with BPH 34 patients with PCa 15 control subjects | BPH group: 64.3 ± 7.9  PCa group: 67.5 ± 8.8  Control group: 65.0 ± 6.0 | (i) MDA  (ii) CuZn-SOD, GPX, CAT measured by a UV–VIS recording spectrophotometer  (iii) NO2−/NO3− concentration with lower GPX and CuZn-SOD activities in PCa patients. | Compared with BPH and control groups, there is a higher MDA and NO2−/NO3− concentration with lower GPX and CuZn-SOD activities in PCa patients. | [54] |
| Pace G, et al. 2010 | Case-control study | 7 patients with BPH 11 patients with PCa 5 healthy subjects | BPH group: 65.14 ± 2.12  PCa group: 62.82 ± 1.74  Control group: 66.00 ± 3.51 | (i) ox-LDL, peroxides, TEAC, and SOD measured in blood samples | The study confirmed a significant imbalance of redox status in patients with BPH and PCa and suggests that oxidative stress may be a determinant in the pathogenesis of these diseases. | [55] |
hydroxynonenal [HNE]) [36], and DNA oxidation (8-hydroxy-2'-deoxyguanosine [8-OHdG]). Although, the biomarkers of measured oxidative stress are indirect and have low specificity, these do provide a noninvasive method in clinical practice.

3. Pathophysiological Role of Oxidative Stress in CVD and Prostatic Diseases

Numerous clinical studies have indicated that oxidative stress plays a role in CVD and prostatic diseases (Table 2). Studies have reported that the level of oxidative stress biomarkers was higher in CVD patients [37–40]. Additionally, current evidence suggests that oxidative stress is associated with the etiology and pathogenesis of the prostatic diseases [9, 41–43]. Hence, the phenomenon of CVD increasing the risk of prostatic diseases may be attributed to oxidative stress (Figure 2).

3.1. Renin-Angiotensin System in CVD and Prostatic Diseases

It is well established that the activation of renin-angiotensin system (RAS) is critically associated with the pathogenesis of hypertension and atherosclerosis [58–60]. Previous studies have reported the existence of local RAS in the prostate, and the overactivity of the RAS may be involved in the pathophysiology of BPH and prostate cancer [61–64]. The RAS includes angiotensinogen, renin, angiotensin conversion enzyme (ACE), angiotensin II (Ang II), and angiotensin receptors. Ang II is a biologically active peptide in the RAS, and its main effector receptor is type 1 receptor (AT₁R) (Figure 2).

The ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been successfully used as antihypertensive medication, and some studies have reported that these drugs have also been used in anticancer therapy [65, 66]. A meta-analysis which included 9 cohort studies with 20267 patients suggested that the use of ACEIs/ARB may be associated with a decreased risk of prostate cancer [65]. However, another meta-analysis of observational studies did not find a significant relationship between the use of ACEIs/ARB and prostate cancer risk [67]. Although it is still controversial, ACEIs or ARBs have been used to reduce the risk of prostate cancer. One study showed that the expression level of AT₁R mRNA was higher in prostate cancer than that in the normal human prostate, based on the data, and ACEIs or ARB may inhibit prostate cancer [68]. Another study reported that the ACEI captopril lowers the risk of prostate cancer, but it was not significant [69]. In BPH patients, a clinical study showed that the use of ARB can improve prostatic hyperplasia [70], whereas other antihypertensive drugs were not effective, which indicates that ARB could ameliorate BPH independently of decreasing blood pressure. The ARB drug Losartan could treat the BPH in spontaneously hypertensive rats (SHRs). The study showed that long-term Losartan treatment restored prostatic blood flow and reduced tissue MDA (oxidative stress marker) in SHRs [71]. These findings suggest that ARB/ACEI may also effective in prostatic diseases.

Traditionally, it has been thought that Ang II can directly achieve vasoconstriction by interacting with AT₁R in vascular smooth muscle. Recently, a novel signalling mechanism for Ang II-induced vascular superoxide (O₂⁻) formation was associated with the development of endothelial dysfunction, hypertension, and atherosclerosis. The source of this increased O₂⁻ seemed to be membrane-bound vascular NADPH oxidases (NOXs) [72, 73]. A study has also reported that angiotensin II also induced the production of ROS prostate cancer cells by upregulating the subunits of NADPH oxidase (NOX) [74]. In addition, another study has found expressions of various NOX isoforms in prostate cancer cell lines and a cross-talk between the endogenous ROS generation by NOX system and the tumorigenic potential [41]. Taken together, the ROS generated by NOX may play the central role connecting CVD and prostatic diseases.

3.2. NOX in CVD and Prostatic Diseases. NOXs are the key enzymes of redox signalling and also the main source of ROS in vivo [75]. ROS are generated by NOX in the pathogenesis of CVD (see Figure 2). In human cells, there are seven isoforms of the NOX family proteins, which are NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1, and DUOX2. NOX1, NOX2, and NOX5 directly generate superoxide anions. Conversely, the NOX4 produces H₂O₂ which may be associated with its localization in the mitochondria in

| Author (year) | Study design | Study population | Age (year) | Markers assessed | Main results | Reference |
|---------------|--------------|------------------|------------|------------------|--------------|-----------|
| Hoque A, et al. 2010 | Nested case-control study | 1808 PCa cases 1805 controls | Case group: 63.62 ± 5.54 | (i) Serum protein carbonyl level measured by a noncompetitive ELISA | The study did not support that oxidative stress plays a role in PCa risk or its aggressiveness in serum protein carbonyl level. | [56] |
| Cimino S, et al. 2014 | Case-control study | 60 BPH patients 40 PCa patients | BPH group: 68 ± 6.4 | (i) The level of total thiol groups (TTG) and glutathione | A significant difference of TTG was observed in BPH and PCa patients, and the level of glutathione was lower in PCa patients. | [57] |

HP: hypertension; CHD: coronary heart disease; O₂⁻: superoxide anion; HIAE: high-intensity aerobic exercise; LIAE: low-intensity aerobic exercise; BFE: blood flow restriction; TBARS: thiobarbituric acid-reactive substances; SOD: the enzyme activities of superoxide dismutase; GPX: glutathione peroxidase; CAT: catalase; Cu: copper; Zn: zinc; NR: not reported; BPH: benign prostatic hyperplasia; PCa: prostate cancer; TEAC: total equivalent antioxidant capacity; a the data from Macedonia; b the data from Turkey; MDA: erythrocyte malondialdehyde; NO₂⁻/NO₃⁻: nitrite/nitrate; 8-OHdG: 8-hydroxy-2'-deoxyguanosine; GST: glutathione s-transferase.

Table 2: Continued.
cardiomyocytes and in the endoplasmic reticulum in endothelial cells [76–78]. Superoxide cannot cross the membranes of these organelles. DUOX1 and DUOX2 also produce H2O2 [79]. The transmembrane subunit P22phox and NOX subtypes (NOX1, NOX2, and NOX4) make up the membrane-bound catalytic core [80]. The NOX4 activity requires P22phox and is also regulated by POLDIP2. Of the seven NOXs, NOX1 and NOX2 play a role in immune defence [81], other NOXs act as the second messenger to participate in the regulation of cell signal pathways and maintain the stability of the intracellular environment [82].

3.2.1. NOX and CVD. The association between increased vascular ROS production and hypertension has been reported in animal models with Ang II induced via NOX activation [72]. Some recent in vitro studies have suggested a pivotal role of the NOX and its subunit p47phox in vascular oxidant stress and the blood pressure response to angiotensin II [83, 84]. The previous studies have reported that the expression of mRNA in NOX1, NOX2, and NOX4 was increased in aortas from animals infused with Ang II [85, 86]. In addition, the expression of NOX2, NOX4, and NOX5 was found to be upregulated by Ang II in endothelial cells [87, 88], and knockout of NOX1, NOX2, and NOX4 in mice can reduce blood-pressure elevation induced by Ang II [86, 89, 90]. Taking together, these data suggest that activation of NOX1, NOX2, NOX4, and NOX5 play an important role in the development of Ang II-induced hypertension.

NOX2 is a major ROS source in the heart, and its activity increases after acute myocardial infarction (AMI). Compared with the normal human cardiomyocytes, the expression of NOX2 was higher in patients with AMI [91]. One study reported that the absence of NOX2 in Apoe−/− mice decreased ROS production, increased NO bioavailability, and reduced aortic atherosclerosis [92]. But Sirker et al. indicated that the overexpression of NOX2 in cardiomyocyte or endothelial cell made no difference to initial infarct size in mice with AMI at 4 weeks [93]. Vendrov et al. [94] suggest that expression of NOX4, but not NOX1 or NOX2, was correlated with increased mitochondrial oxidative stress, mitochondrial and cardiovascular dysfunction, and atherosclerosis in aged mice. The study indicated that NOX4 is a potential therapeutic target for aging-associated cardiovascular disease. The current study also demonstrated that NOX5 expression increased in patients with AMI, especially in infarctions > 12 hours [95]. In summary, the expression of NOX2, NOX4, and NOX5 plays a role in the development of coronary heart disease.

3.2.2. NOX and Prostatic Diseases. Evidence has showed that the aberrant activation of NOX plays a critical role in prostate cancer growth and progression [96, 97]. A recent study showed that NOX expression is directly associated with prostate cancer in mice, and when NOX was inhibited, the expression of HIF-1α in the nucleus was significantly decreased as well as a reduction in the proliferation and colony formation of prostate cancer [98]. Some studies have shown that NOX1 and its transmembrane subunit P22phox and NOX5 are overexpressed in prostate cancer [99–102], and downregulated NOX5 expression can inhibit cell proliferation and tumor growth and induce apoptosis of prostate cancer cells [103]. In addition, studies have reported that...
various isoforms of NOX are found in prostate cancer cell lines, including NOX4, NOX2, and NOX5, which are absent in normal prostate cell lines [104, 105]. An in vitro study has shown that the imbalance of redox homeostasis caused by elevated NOX4-derived ROS signal was the basis of fibroblast-to-myoﬁbroblast differentiation in the diseased prostatic stroma, which indicates NOX4 inhibitors have potential clinical value in the prevention of BPH and prostate cancer [106]. Thus, NOX1, NOX2, NOX4, and NOX5 may be potential targets for therapeutic intervention in prostate cancer.

4. Conclusion

Evidence from clinical and animal studies demonstrates that CVD is associated with prostatic diseases, and oxidative stress may erect a bridge between these diseases; however, the exact mechanism of oxidative stress in CVD and prostatic diseases remains to be further elucidated. We provide a framework for future experimental and clinical studies on the role of known and yet to be discovered oxidative stress in CVD and prostatic diseases. The mechanisms and signaling processes by Ang II increased ROS production via NOX in these diseases is yet to be proved. Furthermore, NOX-derived ROS signals may be a common potential target in therapeutic intervention of CVD and prostatic diseases.

Conflicts of Interest

The authors declare that there are no conflicts of interests.

References

[1] G. A. Roth, G. A. Mensah, C. O. Johnson et al., “Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study,” Journal of the American College of Cardiology, vol. 76, no. 25, pp. 2982–3021, 2020.
[2] GBD 2019 Diseases and Injuries Collaborators, “Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019,” The Lancet, vol. 396, no. 10258, pp. 1204–1222, 2020.
[3] S. J. Berry, D. S. Coffey, P. C. Walsh, and L. L. Ewing, “The development of human benign prostatic hyperplasia with age,” The Journal of Urology, vol. 132, no. 3, pp. 474–479, 1984.
[4] T. Deng, L. Cai, Z. Chen, and G. U. Jia, “Analysis of the burden of prostate cancer in China in 1990 and 2017,” Xixue XinZhi Zazhi, vol. 30, no. 4, pp. 252–259, 2020.
[5] Global Burden of Disease Cancer Collaboration, “Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study,” JAMA Oncology, vol. 5, no. 12, pp. 1749–1768, 2019.
[6] X. Liu, C. Yu, Y. Bi, and Z. J. Zhang, “Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China,” Public Health, vol. 172, pp. 70–80, 2019.
[7] C. J. A. Ramachandra, S. Cong, X. Chan, E. P. Yap, F. Yu, and D. J. Hausenloy, “Oxidative stress in cardiac hypertrophy: From molecular mechanisms to novel therapeutic targets,” Free Radical Biology & Medicine, vol. 166, pp. 297–312, 2021.
[8] T. Münzel, G. G. Camici, C. Maack, N. R. Bonetti, V. Fuster, and J. C. Kovacic, “Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series,” Journal of the American College of Cardiology, vol. 70, no. 2, pp. 212–229, 2017.
[9] U. K. Udensi and P. B. Tchounwou, “Oxidative stress in prostate hyperplasia and carcinoma,” Journal of Experimental & Clinical Cancer Research, vol. 35, no. 1, p. 139, 2016.
[10] G. Gupta-Elera, A. R. Garrett, R. A. Robison, and K. L. O’Neill, “The role of oxidative stress in prostate cancer,” European Journal of Cancer Prevention, vol. 21, no. 2, pp. 155–162, 2012.
[11] J. B. Bourke and J. P. Griffin, “Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy,” British Journal of Urology, vol. 38, no. 1, pp. 18–23, 1966.
[12] K. Sugaya, K. Kadekawa, A. Ikehara et al., “Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia,” International Journal of Urology, vol. 10, no. 11, pp. 569–574, 2003.
[13] M. C. Michel, U. Heemann, H. Schumacher, L. Mehlbuerger, and M. Goepel, “Association of hypertension with symptoms of benign prostatic hyperplasia,” The Journal of Urology, vol. 172, 4, Part 1, pp. 1390–1393, 2004.
[14] I. H. Chen, Y. S. Tsai, and Y. C. Tong, “Correlations among cardiovascular risk factors, prostate blood flow, and prostate volume in patients with clinical benign prostatic hyperplasia,” Urology, vol. 79, no. 2, pp. 409–414, 2012.
[15] E. C. Hwang, S. O. Kim, D. H. Nam et al., “Men with hypertension are more likely to have severe lower urinary tract symptoms and large prostate volume,” LUTS: Lower Urinary Tract Symptoms, vol. 7, no. 1, pp. 32–36, 2015.
[16] X. T. Zeng, H. Weng, J. Xiong et al., “Comparison of clinical and physiological parameters for benign prostatic hyperplasia in hypertensive and normotensive patients,” Frontiers in Physiology, vol. 9, p. 1330, 2018.
[17] S. Navin and V. Ioffe, “The association between hypertension and prostate cancer,” Revista de Urología, vol. 19, no. 2, pp. 113–118, 2017.
[18] B. A. Dickerman, J. E. Torfadottir, U. A. Valdimarsdottir et al., “Midlife metabolic factors and prostate cancer risk in later life,” International Journal of Cancer, vol. 142, no. 6, pp. 1166–1173, 2018.
[19] K. M. Weisman, G. E. Larjiani, M. R. Goldstein, and M. E. Goldberg, “Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men,” Pharmacotherapy, vol. 20, no. 4, pp. 383–386, 2000.
[20] A. I. Neugut, D. J. Rosenberg, H. Ahsan et al., “Association between coronary heart disease and cancers of the breast, prostate, and colon,” Cancer Epidemiology, Biomarkers & Prevention, vol. 7, no. 10, pp. 869–873, 1998.
[21] K. N. Stamatiou, A. G. Alevizos, K. Mihas, A. D. Mariolis, E. Michalodimitrakis, and F. Sofras, “Associations between coronary heart disease, obesity and histological prostate cancer,” International Urology and Nephrology, vol. 39, no. 1, pp. 197–201, 2007.
[22] J. A. Thomas 2nd, L. Gerber, L. L. Bañez et al., “Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study,” Cancer Epidemiology, Biomarkers & Prevention, vol. 21, no. 4, pp. 576–581, 2012.
[55] G. Pace, C. D. Massimo, D. D. Amicis et al., “Oxidative stress in benign prostatic hyperplasia and prostate cancer,” Urologia Internationalis, vol. 85, no. 3, pp. 328–333, 2010.

[56] A. Hoque, C. B. Ambrosone, C. Till et al., “Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial,” Cancer Prevention Research (Philadelphia, Pa.), vol. 3, no. 4, pp. 478–483, 2010.

[57] S. Cimino, V. Favilla, G. I. Russo et al., “Oxidative stress and body composition in prostate cancer and benign prostatic hyperplasia patients,” Anticancer Research, vol. 34, no. 9, pp. 5051–5056, 2014.

[58] G. Nickenig and D. G. Harrison, “The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis,” Circulation, vol. 105, no. 3, pp. 393–396, 2002.

[59] L. Rothermund and M. Paul, “Hypertension and the renin-angiotensin system—evidence from genetic and transgenic studies,” Basic Research in Cardiology, vol. 93, no. 2, 1998.

[60] X. C. Li, J. Zhang, and J. L. Zhuo, “The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases,” Pharmacological Research, vol. 125, Part A, pp. 21–38, 2017.

[61] D. T. Dinh, A. G. Frauman, G. R. Somers et al., “Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT (1) receptor expression in benign prostatic hyperplasia,” The Journal of Pathology, vol. 196, no. 2, pp. 213–219, 2002.

[62] L. Nassis, A. G. Frauman, M. Ohishi et al., “Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia,” The Journal of Pathology, vol. 195, no. 5, pp. 571–579, 2001.

[63] M. E. Fabiani, M. Sourial, W. G. Thomas, C. I. Johnston, C. I. Johnston, and A. G. Frauman, “Angiotensin II enhances noradrenaline release from sympathetic nerves of the rat prostate via a novel angiotensin receptor: implications for the pathophysiology of benign prostatic hyperplasia,” The Journal of Endocrinology, vol. 171, no. 1, pp. 97–108, 2001.

[64] K. Domińska, K. Kowalska, K. A. Urbanek, D. H. Habrowska-Goślińska, T. Ochędalski, and A. W. Piastowska Ciesielska, “The impact of Ang-(1-9) and Ang-(3-7) on the biological properties of prostate cancer cells by modulation of inflammatory and steroidogenesis pathway genes,” International Journal of Molecular Sciences, vol. 21, no. 17, p. 6227, 2020.

[65] Y. Q. Mao, X. Xu, X. Wang, X. Y. Zheng, and L. P. Xie, “Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?,” Oncotarget, vol. 7, no. 6, pp. 6765–6773, 2016.

[66] H. Lindberg, D. Nielsen, B. V. Jensen, J. Eriksen, and T. Skovsgaard, “Angiotensin converting enzyme inhibitors for cancer treatment!”, Acta Oncologica, vol. 43, no. 2, pp. 142–152, 2004.

[67] L. Cao, S. Zhang, C. M. Jia et al., “Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies,” BMC Urology, vol. 18, no. 1, p. 17, 2018.

[68] H. Uemura, H. Ishiguro, N. Nakaigawa et al., “Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor,” Molecular Cancer Therapeutics, vol. 2, no. 11, pp. 1139–1147, 2003.

[69] G. Ronquist, L. A. Rodríguez, A. Ruigómez et al., “Association between captopril, other antihypertensive drugs and risk of prostate cancer,” Prostate, vol. 58, no. 1, pp. 50–56, 2004.

[70] H. Ito, M. Taga, K. Tsuchiyama, H. Akino, and O. Yokoyama, “IPSS is lower in hypertensive patients treated with angiotensin-II receptor blocker: posthoc analyses of a lower urinary tract symptoms population,” Neurourology and Urodynamics, vol. 32, no. 1, pp. 70–74, 2013.

[71] S. Shimizu, Y. Nagao, T. Shimizu, Y. Higashi, T. Karashima, and M. Saito, “Therapeutic effects of losartan on prostatic hyperplasia in spontaneously hypertensive rats,” Life Sciences, vol. 266, article 118924, 2021.

[72] S. Rajagopalan, S. Kurz, T. Münzel et al., “Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone,” The Journal of Clinical Investigation, vol. 97, no. 8, pp. 1916–1923, 1996.

[73] U. Rueckeschloss, M. T. Quinn, J. Holtz, and H. Morawietz, “Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial Cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 11, pp. 1845–1851, 2002.

[74] H. Uemura, H. Ishiguro, Y. Ishiguro, K. Hoshino, S. Takahashi, and Y. Kubota, “Angiotensin II induces oxidative stress in prostate cancer,” Molecular Cancer Research, vol. 6, no. 2, pp. 250–258, 2008.

[75] N. Y. Spencer and J. F. Engelhardt, “The basic biology of redoxosomes in cytokine-mediated signal transduction and implications for disease-specific therapies,” Biochemistry, vol. 53, no. 10, pp. 1551–1564, 2014.

[76] S. Dikalov, A. Dikalova, A. Bikineyeva, H. Schmidt, D. Harrison, and K. Griendling, “Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production,” Free Radical Biology & Medicine, vol. 45, no. 9, pp. 1340–1351, 2008.

[77] I. Helmcke, S. Heumüller, R. Tikkanen, K. Schröder, and R. P. Brandes, “Identification of structural elements in Nox1 and Nox4 controlling localization and activity,” Antioxidants & Redox Signaling, vol. 11, no. 6, pp. 1279–1287, 2009.

[78] K. Block, Y. Gorin, and H. E. Abboud, “Subcellular localization of Nox4 and regulation in diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 34, pp. 14385–14390, 2009.

[79] J. D. Lambeth, T. Kawahara, and B. Diebold, “Regulation of Nox and Duox enzymatic activity and expression,” Free Radical Biology & Medicine, vol. 45, no. 3, pp. 319–331, 2007.

[80] R. P. Brandes, N. Weissmann, and K. Schröder, “Nox family NADPH oxidases: molecular mechanisms of activation,” Free Radical Biology & Medicine, vol. 76, pp. 208–226, 2014.

[81] M. Torres, “Mitogen-activated protein kinase pathways in redox signalling,” Frontiers in Bioscience, vol. 8, pp. 369–391, 2003.

[82] S. Mao and S. Huang, “The signaling pathway of NADPH oxidase and its role in glomerular diseases,” Journal of Receptor and Signal Transduction Research, vol. 34, no. 1, pp. 6–11, 2014.

[83] M. C. Lavigne, H. L. Malech, S. M. Holland, and T. L. Leto, “Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells,” Circulation, vol. 104, no. 1, pp. 79–84, 2001.
[84] U. Landmesser, H. Cai, S. Dikalov et al., "Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II," Hypertension, vol. 40, no. 4, pp. 511–515, 2002.

[85] M. Higashi, H. Shimokawa, T. Hattori et al., "Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system," Circulation Research, vol. 93, no. 8, pp. 767–775, 2003.

[86] K. Matsuno, H. Yamada, K. Iwata et al., "NADPH oxidase-dependent mitochondrial oxidative stress in aging-associated cardiovascular disease," NADPH oxidase-dependent mitochondrial oxidative stress, vol. 23, no. 18, pp. 1389–1395, 2015.

[87] G. Z. Liang, L. M. Cheng, X. F. Chen et al., "Increased Nox1 and hydrogen peroxide in prostate cancer," Prostate, vol. 62, no. 2, pp. 200–207, 2005.

[88] A. C. Montezano, D. Burger, T. M. Paravicini et al., "Role of NADPH oxidase subunit p22(phox) in reactive oxygen species production in intramyocardial blood vessels and cardiomyocytes after acute myocardial infarction in humans, and during transient ischemia. A study in Nox1-deficient mice," Circulation, vol. 112, no. 17, pp. 2677–2685, 2005.

[89] H. D. Wang, S. Xu, D. G. Johns et al., "Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice," Circulation Research, vol. 88, no. 9, pp. 947–953, 2001.

[90] G. Bouabout, E. Ayme-Dietrich, H. Jacob et al., "Effets de l’inhibition constitutive de la Nox4 dans l’hypertension arterielle experimentale et le syndrome metabolique," Archives of Cardiovascular Diseases, vol. 111, no. 1, pp. 41–52, 2018.

[91] P. A. Krijnen, C. Meischl, C. E. Hack et al., "Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction," Journal of Clinical Pathology, vol. 56, no. 3, pp. 194–199, 2003.

[92] C. P. Judkins, H. Diep, B. R. S. Broughton et al., "Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE/−/− mice," American Journal of Physiology. Heart and Circulatory Physiology, vol. 298, no. 1, pp. 24–32, 2010.

[93] A. Sirker, C. E. Murdoch, A. Protti et al., "Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction," Journal of Molecular and Cellular Cardiology, vol. 98, pp. 11–17, 2016.

[94] A. E. Vendrov, K. C. Vendrov, A. Smith et al., "NOX4 NADPH oxidase-dependent mitochondrial oxidative stress in aging-associated cardiovascular disease," Antioxidants & Redox Signaling, vol. 23, no. 18, pp. 1389–1409, 2015.

[95] N. E. Hahn, C. Meischl, T. Kawahara et al., "NOX5 expression is increased in intramyocardial blood vessels and cardiomyocytes after acute myocardial infarction in humans," The American Journal of Pathology, vol. 180, no. 6, pp. 2222–2229, 2012.

[96] K. Roy, Y. Wu, J. L. Meitzler et al., "NADPH oxidases and cancer," Clinical Science (London, England), vol. 128, no. 12, pp. 863–875, 2015.

[97] K. Block and Y. Gorin, "Aiding and abetting roles of NOX oxidases in cellular transformation," Nature Reviews. Cancer, vol. 12, no. 9, pp. 627–637, 2012.

[98] G. Deep, R. Kumar, A. K. Jain et al., "Graviola inhibits hypoxia-induced NADPH oxidase activity in prostate cancer cells reducing their proliferation and clonogenicity," Scientific Reports, vol. 6, no. 1, article 23135, 2016.

[99] S. D. Lim, C. Sun, J. D. Lambeth et al., "Increased Nox1 and hydrogen peroxide in prostate cancer," Prostate, vol. 62, no. 2, pp. 200–207, 2005.

[100] M. Höll, R. Koziel, G. Schäfer et al., "ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells," Molecular Carcinogenesis, vol. 55, no. 1, pp. 27–39, 2016.

[101] V. Laurent, A. Toulet, C. Attané et al., "Periprostatic adipose tissue favors prostate cancer cell invasion in an obesity-dependent manner: role of oxidative stress," Molecular Cancer Research, vol. 17, no. 3, pp. 821–835, 2019.

[102] Q. Li, G. B. Fu, J. T. Zheng et al., "NADPH oxidase subunit p22(phox) mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer," Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1833, no. 12, pp. 3375–3385, 2013.

[103] S. S. Brar, Z. Corbin, T. P. Kennedy et al., "NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells," American Journal of Physiology. Cell Physiology, vol. 285, no. 2, pp. 353–369, 2003.

[104] L. Khandrika, B. Kumar, S. Koul, H. K. Koul, and H. K. Koul, "Oxidative stress in prostate cancer," Cancer Letters, vol. 282, no. 2, pp. 125–136, 2009.

[105] Y. Miyata, T. Matsuo, Y. Sagara, K. Ohba, K. Ohyama, and H. Sakai, "A mini-review of reactive oxygen species in urological cancer: correlation with NADPH oxidases, angiogenesis, and apoptosis," International Journal of Molecular Sciences, vol. 18, no. 10, article 2214, 2017.

[106] N. Sampson, R. Koziel, C. Zenzmaier et al., "ROS Signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma," Molecular Endocrinology, vol. 25, no. 3, pp. 503–515, 2011.